KROS-401 / Kairos Pharma - LARVOL DELTA

Targeting M2 macrophage polarization: The anti-tumor effects of IL-4/IL-13 blocking peptide and iron oxide nanoparticles (Businesswire) - "Kairos Pharma...announced that the company presented preclinical data on its investigational compounds...during the American Association for Cancer Research Immuno-Oncology (AACR IO) conference....The second presentation...demonstrated the Company’s peptide inhibitor KROS 401 may effectively reprogram macrophages - types of white blood cell of the innate immune system that engulf and digest pathogens, such as cancer cells, microbes, cellular debris and foreign substances – to inhibit tumor growth. The preclinical study demonstrated that KROS 401 exhibited an anti-tumor effect in glioma-bearing mice following a decrease in M2 macrophages, which are known to facilitate tumor growth."

Preclinical • Glioma

Kairos Pharma Receives FDA Approval of Investigational New Drug (IND) Application for Its Phase 1 Clinical Trial of KROS 201 for the Treatment of Glioblastoma; Announces New Patent for KROS 401 (PRNewswire) - "Kairos Pharma...announced that its activated T cell therapy, KROS 201, has received FDA approval to proceed with a Phase 1 clinical trial in patients with recurrent glioblastoma, a type of brain cancer. The phase I trial is sponsored by Kairos Pharma and will be conducted at Cedars Sinai Medical Center in Los Angeles....A Phase 1 trial of ENV105 with Tagrisso (AstraZeneca) for lung cancer is planned to start in 2022....New patent covers the method of treating fibrosis and certain forms of cancer, the composition of matter, and administering a therapy using KROS-401."

IND • New P1 trial • Patent • Brain Cancer • Glioblastoma • Lung Cancer • Oncology • Solid Tumor